Media Coverage
Stifel’s Mid-2024 Halftime Report, packed with DealForma data, on the biotech market highlights the mixed investor sentiment, strong mid-sized M&A activity, improving inflation, and a predicted robust but bumpy market recovery for the rest of the year. Explore Stifel’s research.
Stifel’s latest update, partly using DealForma data, reviews recent data and updates on the rapidly advancing obesity pharmaceutical market, including insights from the American Diabetes Association and upcoming EASD abstracts. Explore Stifel’s research.
Stifel’s latest update, using DealForma data, reports key oncology pharma market trends, including substantial ASCO conference activity, game-changing therapies, and rising cancer drug spending. Explore the full oncology update.
Stifel’s latest update, using DealForma data, reports key biopharma market events. Highlights include hawkish Fed impacts on biotech stocks, Biogen’s $1.15B HI-Bio acquisition, and $1.7B in follow-on offerings. Checkout the Stifel story.
David H. Crean highlights robust activity in life sciences for Q1 2024, featuring key M&As, IPOs, and venture funding, despite economic challenges, as detailed by DealForma data. Read the full report
Venture investment in biopharma and medtech has remained strong through the first quarter of 2024, as detailed in J.P. Morgan’s latest report, which utilizes data compiled by DealForma. Download the reports
Stifel’s recent report, leveraging data from the DealForma database, highlights key trends in biopharma M&A, including a rise in high-value deals and significant activity in immunology and oncology sectors. Checkout the Stifel story
Artificial intelligence and machine learning are changing the pharmaceutical sector, affecting drug discovery, clinical trials, and other areas, according to a report by Stifel that used Dealforma’s data. Checkout the Stifel story
DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising new questions about just how deep and lasting this biotech recovery can be. Checkout the Endpoints News story
Tim Opler and the team at Stifel put together a chart-packed weekly report on biopharmaceutical sector. DealForma was happy to contribute the data.
In January 2024, the rare disease therapeutics sector experienced a funding surge to nearly $3 billion, indicating a strong start to the year.
Endpoints News’ John Carroll and DealForma’s Chris Dokomajilar hosted a special webinar to discuss their latest ranking of the top 100 biotech VCs, examining the challenges and opportunities in a market facing an IPO drought and investor hesitancy. Listen to the webinar here.
